Literature DB >> 19043708

Phenotypic and functional alterations of Vgamma2Vdelta2 T cell subsets in patients with active nasopharyngeal carcinoma.

Kia Joo Puan1, John Seng Hooi Low, Terence Wee Kiat Tan, Joseph Tien Seng Wee, Eng Huat Tan, Kam Weng Fong, Eu Tiong Chua, Chenggang Jin, José-Luis Giner, Craig T Morita, Christopher Hood Keng Goh, Kam M Hui.   

Abstract

INTRODUCTION: Human Vgamma2Vdelta2 T cells play important role in immunity to infection and cancer by monitoring self and foreign isoprenoid metabolites with their gammadelta T cell antigen receptors. Like CD4 and CD8 alphabeta T cells, adult peripheral Vgamma2Vdelta2 T cells represent a pool of heterogeneous cells with distinct functional capabilities.
PURPOSE: The aim of this study was to characterize the phenotypes and functions of various Vgamma2Vdelta2 T cell subsets in patients with nasopharyngeal carcinoma (NPC). We sought to develop a better understanding of the role of these cells during the course of disease and to facilitate the development of immunotherapeutic strategies against NPC.
RESULTS: Although similar total percentages of peripheral blood Vgamma2Vdelta2 T cells were found in both NPC patients and normal donors, Vgamma2Vdelta2 T cells from NPC patients showed decreased cytotoxicity against tumor cells whereas Vgamma2Vdelta2 T cells from normal donors showed potent cytotoxicity. To investigate further, we compared the phenotypic characteristics of Vgamma2Vdelta2 T cells from 96 patients with NPC and 54 healthy controls. The fraction of late effector memory Vgamma2Vdelta2 T cells (T(EM RA)) was significantly increased in NPC patients with corresponding decreases in the fraction of early memory Vgamma2Vdelta2 T cells (T(CM)) compared with those in healthy controls. Moreover, T(EM RA) and T(CM) Vgamma2Vdelta2 cells from NPC patients produced significantly less IFN-gamma and TNF-alpha, potentially contributing to their impaired cytotoxicity. Radiotherapy or concurrent chemo-radiotherapy further increased the T(EM RA) Vgamma2Vdelta2 T cell population but did not correct the impaired production of IFN-gamma and TNF-alpha observed for T(EM RA) Vgamma2Vdelta2 T cells.
CONCLUSION: We have identified distinct alterations in the Vgamma2Vdelta2 T cell subsets of patients with NPC. Moreover, the overall cellular effector function of gammadelta T cells is compromised in these patients. Our data suggest that the contribution of Vgamma2Vdelta2 T cells to control NPC may depend on the activation state and differentiation of these cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19043708      PMCID: PMC2695875          DOI: 10.1007/s00262-008-0629-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  57 in total

1.  Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.

Authors:  Francesco Dieli; Nicola Gebbia; Fabrizio Poccia; Nadia Caccamo; Carla Montesano; Fabio Fulfaro; Carlo Arcara; Maria R Valerio; Serena Meraviglia; Caterina Di Sano; Guido Sireci; Alfredo Salerno
Journal:  Blood       Date:  2003-09-15       Impact factor: 22.113

Review 2.  Lessons from the study of T-cell differentiation in persistent human virus infection.

Authors:  Victor Appay; Sarah L Rowland-Jones
Journal:  Semin Immunol       Date:  2004-06       Impact factor: 11.130

3.  Distinct subpopulations of gamma delta T cells are present in normal and tumor-bearing human liver.

Authors:  Tony Kenna; Lucy Golden-Mason; Suzanne Norris; John E Hegarty; Cliona O'Farrelly; Derek G Doherty
Journal:  Clin Immunol       Date:  2004-10       Impact factor: 3.969

4.  Gamma interferon production, but not perforin-mediated cytolytic activity, of T cells is required for prevention of toxoplasmic encephalitis in BALB/c mice genetically resistant to the disease.

Authors:  Xisheng Wang; Hoil Kang; Takane Kikuchi; Yasuhiro Suzuki
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

5.  Gamma delta T cell receptor-bearing lymphocytes during Epstein-Barr virus infection.

Authors:  P De Paoli; D Gennari; P Martelli; V Cavarzerani; R Comoretto; G Santini
Journal:  J Infect Dis       Date:  1990-05       Impact factor: 5.226

6.  Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

Authors:  Keith Thompson; Michael J Rogers
Journal:  J Bone Miner Res       Date:  2003-12-16       Impact factor: 6.741

Review 7.  Central memory and effector memory T cell subsets: function, generation, and maintenance.

Authors:  Federica Sallusto; Jens Geginat; Antonio Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

8.  Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites.

Authors:  Francesco Dieli; Fabrizio Poccia; Martin Lipp; Guido Sireci; Nadia Caccamo; Caterina Di Sano; Alfredo Salerno
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307

Review 9.  Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection.

Authors:  Laura Papagno; Celsa A Spina; Arnaud Marchant; Mariolina Salio; Nathalie Rufer; Susan Little; Tao Dong; Gillian Chesney; Anele Waters; Philippa Easterbrook; P Rod Dunbar; Dawn Shepherd; Vincenzo Cerundolo; Vincent Emery; Paul Griffiths; Christopher Conlon; Andrew J McMichael; Douglas D Richman; Sarah L Rowland-Jones; Victor Appay
Journal:  PLoS Biol       Date:  2004-02-17       Impact factor: 8.029

10.  Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells.

Authors:  Shayna E A Street; Yoshihiro Hayakawa; Yifan Zhan; Andrew M Lew; Duncan MacGregor; Amanda M Jamieson; Andreas Diefenbach; Hideo Yagita; Dale I Godfrey; Mark J Smyth
Journal:  J Exp Med       Date:  2004-03-08       Impact factor: 14.307

View more
  9 in total

Review 1.  Quantitative peripheral blood perturbations of γδ T cells in human disease and their clinical implications.

Authors:  Ilan Bank; Victoria Marcu-Malina
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 2.  Harnessing the power of Vδ2 cells in cancer immunotherapy.

Authors:  D W Fowler; M D Bodman-Smith
Journal:  Clin Exp Immunol       Date:  2015-04       Impact factor: 4.330

3.  Radiation-induced DNA damage and repair in human gammadelta and alphabeta T-lymphocytes analysed by the alkaline comet assay.

Authors:  Halina Lisowska; Marta Deperas-Kaminska; Siamak Haghdoost; Ingela Parmryd; Andrzej Wojcik
Journal:  Genome Integr       Date:  2010-06-08

Review 4.  Complex role of γδ T-cell-derived cytokines and growth factors in cancer.

Authors:  Andrew G Ramstead; Mark A Jutila
Journal:  J Interferon Cytokine Res       Date:  2012-10-18       Impact factor: 2.607

5.  Metabolic engineering of Salmonella vaccine bacteria to boost human Vγ2Vδ2 T cell immunity.

Authors:  Grefachew Workalemahu; Hong Wang; Kia-Joo Puan; Mohanad H Nada; Tomohisa Kuzuyama; Bradley D Jones; Chenggang Jin; Craig T Morita
Journal:  J Immunol       Date:  2014-06-18       Impact factor: 5.422

6.  Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.

Authors:  Mohanad H Nada; Hong Wang; Grefachew Workalemahu; Yoshimasa Tanaka; Craig T Morita
Journal:  J Immunother Cancer       Date:  2017-02-21       Impact factor: 13.751

7.  Potentiating Vγ9Vδ2 T cell proliferation and assessing their cytotoxicity towards adherent cancer cells at the single cell level.

Authors:  Chenxiao Liu; Karolina Skorupinska-Tudek; Sven-Göran Eriksson; Ingela Parmryd
Journal:  Biol Open       Date:  2022-02-07       Impact factor: 2.422

8.  Vδ2+ and α/ß T cells show divergent trajectories during human aging.

Authors:  Crystal Tze Ying Tan; Kilian Wistuba-Hamprecht; Weili Xu; Ma Schwe Zin Nyunt; Anusha Vasudev; Bernett Teck Kwong Lee; Graham Pawelec; Kia Joo Puan; Olaf Rotzschke; Tze Pin Ng; Anis Larbi
Journal:  Oncotarget       Date:  2016-07-19

Review 9.  The T-cell Response to Epstein-Barr Virus-New Tricks From an Old Dog.

Authors:  Heather M Long; Benjamin J Meckiff; Graham S Taylor
Journal:  Front Immunol       Date:  2019-09-18       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.